Efficacy and safety profile of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results)

Abate, Michele; Verna, Sandra; Schiavone, Cosima; Gregorio, Patrizia Di; Salini, Vincenzo

doi:10.1007/s00590-015-1693-3

Cited by 43 publications

(58 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cellular Matrix is the first dedicated medical device allowing to prepare PRP in presence of HA in a simple, safe and reproducible procedure. Abate et al [40] conducted a retrospective comparative study on a patient group treated with PRP only compared to a patient group treated with the Cellular Matrix CM-PRP-HA combination. Interestingly, in this study, the device used to prepare PRP (RegenKit-BCT, Regen Lab, Switzerland) was based on the same technology as Cellular Matrix, except that it didn't contain HA and the PRP volume was almost twofold that of Cellular Matrix.…”

Section: Research Articlementioning

confidence: 99%

“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up

Renevier¹,

Marc²,

Adam³

et al. 2018

Int. J. Clin. Rheumatol

View full text Add to dashboard Cite

To evaluate the safety and efficacy of Cellular Matrix™, a new medical device designed for one-step preparation of platelet-rich plasma in presence of hyaluronic acid, for the management of tibiofemoral knee osteoarthritis in patients who had failed to respond adequately to previous treatment with hyaluronic acid alone. Methods: Multicentre, open-label, uncontrolled, pilot study in 77 patients with grade II or III knee osteoarthritis and a pain at walking score between 3 and 8 on a Numeric Rating Scale. The treatment consisted of a series of 3 intra-articular injections scheduled at D0, D60 and D180 into the affected knee of a combination of platelet-rich plasma and hyaluronic acid prepared with the device Cellular Matrix. The primary efficacy criterion was the variation of pain at walking, as assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (A1 score) between baseline and D270. Results: Treatment with the combination of platelet-rich plasma and hyaluronic acid prepared with Cellular Matrix significantly reduced pain at walking between baseline and D270. The percentage of responders according to the criteria of the Outcome Measures in Rheumatology Clinical Trial and Osteoarthritis Research Society International was 94.4%. The treatment provided long-lasting benefits for half of the patients and allowed avoiding surgery for almost 80% of them at four years. Conclusion: A 3-injection course of a combination of platelet-rich plasma and hyaluronic acid prepared with Cellular Matrix was well tolerated and effective in the long-term to relieve pain associated with symptomatic knee osteoarthritis.

show abstract

Section: Research Articlementioning

confidence: 99%

“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up

Renevier¹,

Marc²,

Adam³

et al. 2018

Int. J. Clin. Rheumatol

View full text Add to dashboard Cite

show abstract

“…CM-PRP-HA provided long-lasting benefits for half of the patients and allowed avoiding surgery for almost 80% of them at four years. Another study retrospectively compared patients treated with CM-PRP-HA (40 patients) to a control group treated with PRP only [67]. The treatment was based on 3 intra-articular injections administered at weekly intervals.…”

Section: Clinical Resultsmentioning

confidence: 99%

“…It has similar characteristics to Ostenil ® Plus (TRB Chemedica, Switzerland) however without the adjunction of mannitol. When injected into a joint, this HA network not only brings visco-supplementation in the intraarticular space, but also entraps the platelets and the plasma molecules, which probably optimize the biological action of the PRP [67].…”

Section: Research Articlementioning

confidence: 99%

Technology rationale for the development of CellularMatrix® A-CP-HA Kit, certified medical device allowing the combination of platelet rich plasma and hyaluronic acid for the treatment of osteoarthritis

Vischer¹,

Fourmestraux²,

Turzi³

2018

nt. J. Clin. Rheumatol

View full text Add to dashboard Cite

International Journal of Clinical Rheumatology Opinion Article Technology rationale for the development of CellularMatrix® A-CP-HA Kit, certified medical device allowing the combination of platelet rich plasma and hyaluronic acid for the treatment of osteoarthritis The composition of synovial fluid of patients suffering from osteoarthritis (OA) is altered with reduced concentration and molecular weight of Hyaluronic Acid (HA) and augmentation of catabolic enzymes and inflammatory markers. Intra-Articular (IA) injections of exogenous HA aim to restore the rheological properties of the synovial fluid in the osteoarthritic joints. However, clinical studies have shown that the benefit of HA injections lasts only for around 6 months and that many patients don't respond well to repeated course of HA treatment. On the other side, platelet rich plasma (PRP) IA injections have been shown to reduce pain and improve joint mobility, probably by modulating the expression of catabolic enzymes and inflammatory markers. As injections of HA and PRP use different pathway to alleviate symptoms in OA patients, the concept of combining these two treatments has emerged recently. In vitro evaluations and preliminary studies have demonstrated the therapeutic potential of this new therapeutic approach for OA treatment. To meet the needs of medical practitioners that want to treat their patients with this new treatment option, an innovative medical device, the CellularMatrix A-CP-HA Kit, has been specifically designed. This device is the first certified medical device that allows the combination of PRP and HA in manner compliant with medical devices regulation and good clinical practice.

show abstract

“…Our study showed similar results. However, a study published in 2015 compared Cellular Matrix and PRP with PRP alone in the treatment of mild and moderate knee OA and showed that there is no difference in the treatment outcome between those two procedures [20].…”

Section: Discussionmentioning

confidence: 99%

The use of cellular matrix in symptomatic knee osteoarthritis

Abbassy

Trebinjac

Kotb³

2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Knee osteoarthritis is a degenerative "wear and tear" disorder affecting mainly population over 50 years old. It can also present in younger people, especially after an injury or as a part of other diseases. While many therapeutic options exist for knee osteoarthritis, none of them has the potential to cure this condition. Cellular Matrix represents a combination of natural non-crosslinked hyaluronic acid (HA), thixotropic cell separation gel, and sodium citrate anticoagulant solution. A combination of Cellular Matrix with autologous platelet-rich plasma (A-PRP) is a novel therapeutic approach to the management of knee osteoarthritis. It is assumed that the active components HA and PRP have a synergistic effect contributing to a better therapeutic outcome in patients with knee osteoarthritis. Physiotherapy could provide an additional benefit. This is a retrospective pilot study assessing the potential benefit of Cellular Matrix and A-PRP combined with physiotherapy in the management of chronic knee osteoarthritis. Twenty-five patients were enrolled in the study and injected with three doses of Cellular Matrix combined with A-PRP with a time span of 2 weeks between each injection. All patients received standardized physiotherapy. The results showed that 68% of patients achieved more than 50% improvement in pain, stiffness, and function of the knee joints. There were no adverse reactions. This retrospective pilot study confirmed the positive effect of PRP and HA combination in the management of mild and moderate knee osteoarthritis. These preliminary results need to be verified in randomized control trials.

show abstract

Efficacy and safety profile of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results)

Abstract: The association of platelet-rich plasma + hyaluronic acid has the same efficacy of platelet-rich plasma only, administered in higher volume. We may infer that hyaluronic acid works synergically and improves the activity of several molecules contained in platelet-rich plasma.

Cited by 43 publications

References 19 publications

“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up

“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up

Technology rationale for the development of CellularMatrix® A-CP-HA Kit, certified medical device allowing the combination of platelet rich plasma and hyaluronic acid for the treatment of osteoarthritis

The use of cellular matrix in symptomatic knee osteoarthritis

Contact Info

Product

Resources

About